OR WAIT null SECS
Immodulon has received an indication of allowability from the European Patent Office for the claims in its patent application relating to its lead drug candidate.
Immuno-oncology company, Immodulon, has announced, in a June 8, 2021 press release, the receipt of an indication of allowability from the European Patent Office for the claims in its patent application relating to its lead drug candidate, IMM-101.
The patent application specifically relates to combining IMM-101 with various classes of immune checkpoint inhibitors (CPIs) for the treatment of any tumor type. If granted, the patent will further support the company’s intellectual property (IP) position around the lead drug candidate ahead of the commencement of a potentially pivotal study in 2022, and the expiration of the patent would be in 2034.
“We are pleased to have received this indication of allowability of the claims for this key European Patent Application that will bolster our IP position around IMM-101, our lead drug candidate, in combination with immune checkpoint inhibitors as a treatment for cancer,” said Jaap Kampinga, CEO of Immodulon, in the press release. “IMM-101 has a unique mechanism of action—principally activating dendritic cells of the human immune system via the Toll-Like receptor 2. Studies to date suggest that IMM-101 is synergistic to the effects of the main classes of checkpoint inhibitors and presents no added safety burden.”
Furthermore, Kampinga stated in the press release that the company has an open investigational new drug application in the United States for the lead drug candidate in sarcoma and has also been given orphan drug designation in the European Union and the US for treatment of pancreatic cancer.